Distribution, dynamic evolution, and clinical outcomes of patients with advanced breast cancer according to HER2 expression

BACKGROUND: Novel antibody‒drug conjugates (ADC) have shown great efficacy in HER2-low advanced breast cancer. However, the clinical features of HER2-low disease still need to be clarified. The current study aims to evaluate the distribution and dynamic change in HER2 expression in patients with dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Qin, Yu, Jing, Liu, Deyue, Ren, Fang, Wu, Jiayi, Shen, Kunwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9942407/
https://www.ncbi.nlm.nih.gov/pubmed/36810001
http://dx.doi.org/10.1186/s12885-023-10634-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9942407/
https://www.ncbi.nlm.nih.gov/pubmed/36810001
http://dx.doi.org/10.1186/s12885-023-10634-7

Ejemplares similares